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Research Question? Call the Office of Research at our central number: (413) 794-3391
Clinical Trials Office (CTO) launched
Clinical trials research is 
integral to Baystate Health’s 
identity. It offers state-of-the-
art treatments to our patients 
in western Massachusetts. It 
enables Baystate Health to 
collaborate with pharmaceutical 
and device manufacturers that 
are creating the next generation 
of therapeutic interventions. In 
addition, clinical trials research 
promotes both the quality and 
diversity of faculty through aca-
demic engagement, enhances 
the recruitment and retention of 
skilled professionals by creating 
an atmosphere of scholarly 
inquiry, and raises the local, 
regional and national stature of 
the institution. 
According to clinicaltrials.
gov, a clinical trial, by definition, 
“involves research using human 
volunteers (participants) that 
is intended to add to medical 
knowledge. Participants receive 
specific interventions (like drugs, 
devices, or procedures) accord-
ing to the research plan or pro-
tocol created by the investiga-
tors.” Such studies are essential 
to advance evidence-based 
medical practice. However, 
the regulatory and operational 
demands of clinical trials have 
magnified in recent decades. 
To meet these challenges, the 
Office of Research launched the 
new Baystate Health Clinical 
Trials Office (CTO) in September 
2018.
“Given the tremendous 
expense of health care, all 
sectors in our society have a 
vested interest in finding better 
strategies of patient evalua-
tion and treatment,” says Jay 
Steingrub, MD, Director of 
the new Clinical Trials Office. 
“Such important efforts need 
to encompass the biological 
sciences, epidemiology, use 
of new technologies and other 
health care related resources. 
Research is critical to the future 
of health care; without support-
ing research we are left with a 
myopic acceptance of the cur-
rent therapeutic and diagnostic 
limitations for our patients.”
BUILDING THE CLINICAL 
TRIALS OFFICE
After over a year of planning, 
the CTO has been set up to 
provide new infrastructure for 
clinical trials at Baystate Health. 
The goal is to advance Bay-
state’s capabilities to participate 
in industry-sponsored clinical 
trials. The initial approach 
is to concentrate on those 
services most sought after by 
industry and by our own faculty. 
These include such elements 
as a single point of contact, 
improved contracting efficiency, 
an up-to-date investigator 
database, appropriate facilities 
for company monitors, and 
assistance with planning and 
executing studies, including 
nurse coordinator services. 
“The CTO is expanding its 
role to include the development 
of patient recruitment ser-
vices, training and educational 
programs for nurse coordinators 
and research assistants and 
physician investigators and 
eventually the development of a 
satellite site network at Baystate 
Franklin Medical Center,” says 
Steingrub. “Perhaps the most 
unique aspiration for the CTO 
is comprehensiveness. The 
goal of the CTO is to provide 
one-stop shopping in that all the 
resources required for conduct-
ing a clinical trial at Baystate are 
available within the CTO team.”
Everyday activities of the CTO 
rely on coordinating the activi-
ties of the entire team within the 
Office of Research, including 
Sponsored Programs Adminis-
tration and the Human Research 
Protection Program. This 
collaboration will make spon-
sor interactions with Baystate 
efficient and effective. It will 
also reduce the usual start up 
barriers facing new investigators 
who want to become involved in 
the clinical trials process. 
“More than anything else, 
it’s the ease of working with 
a group that is dedicated to 
the same goals; that is timely, 
accurate and reliable comple-
tion of important clinical trials,” 
adds Steingrub. “This is our mis-
sion: for the CTO to support the 
effective, efficient and reliable 
evaluation of new pharmaceu-
ticals, and medical devices in 
collaboration with sponsoring 
organizations, including industry 
and government.”
Lori Kozikowski, RN, BSN, 
CTO Program Director, shares 
Jay Steingrub, MD, Director of the Center for Clinical Trials and Translational 
Investigation, and Lori-Ann Kozikowski, RN, BSN, CTO Program Director.
(Continued on page 2)
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this vision.
“All components of the CTO 
will fall under one umbrella,” 
she says. “The CTO continues 
to grow and we are working 
hard to make it less onerous to 
start and operate clinical trials at 
Baystate.” As Program Director, 
Kozikowski is available to clini-
cal trial and research person-
nel at Baystate to help with 
compliance issues, quality, data 
integrity, training and educating 
new research staff, and stable 
workforce planning. She is com-
mitted to providing the neces-
sary tools and education to our 
researchers.
THE FUTURE OF CLINICAL 
TRIALS AT BAYSTATE
The Baystate CTO links to 
researchers and patients at 
other institutions and in other 
communities as well. 
“The CTO has created an 
avenue for not only our external 
subjects, but also for UMass 
Amherst and UMass Worcester 
scientists to better align with our 
doctors and researchers here 
at Baystate,” Steingrub adds. 
“Through our research, many 
of our discoveries are able 
to be shared with the clinical 
population.” 
“It’s all about addressing the 
needs of the population,” says 
Kozikowski. “When people are 
sick, they want options. They 
don’t want to have to go to 
Boston or Hartford for the care 
they are looking for. If research 
is available to people, they’re 
willing to listen and make a 
choice.”
Clinical research is central to 
Baystate’s mission of demon-
strating how medical advances 
can and should be applied to 
improve human health. 
“We at Baystate have 
recognized that to ensure our 
continued involvement in such 
activity we must change the way 
we do business with industry 
sponsors,” concludes Steingrub. 
“It is the CTO’s firm belief that 
clinical research in general, and 
industry sponsored trials in par-
ticular; belong at our academic 
medical center. To date, industry 
reactions to our CTO services 
have been enthusiastic.”
The CTO team looks forward 
to partnering with clinicians, 
scientists, staff, patients and 
families to expand opportuni-
ties for clinical trials and thus 
advance the state of caring at 
Baystate Health.
FOR MORE INFORMATION:
If you are interested 
in learning more or par-
ticipating in a clinical trial 
at Baystate, visit www.
baystatehealth.org/patients/
learn-about-clinical-trials.
Jennifer Pacheco, MPH, 
CIM, CIP promoted to Chief 
Research Compliance Officer
A Hello from the 
[New] Editor
Hi everyone, 
For those of 
you who don’t 
know me, my 
name is Allison 
Litera (most 
people call me 
Allie). I am the 
Digital Content 
Analyst for the 
Offices of Faculty 
Affairs and 
Research here at 
UMMS-Baystate. 
I have been part 
of the team since 
October 2018 and am thrilled to be bringing 
back The Innovator as the writer, editor, and 
designer of this quarterly publication.
I’ve been a resident of the Pioneer Valley 
my entire life. I graduated from the Hartford Art 
School in 2012 with a BFA in illustration and 
an art history minor. I’m an all-around creative 
person. When I’m not working full time, I am a 
freelance caricature artist, crafter, writer, and 
photographer. 
Since I do not come from a medical 
background myself, it is my hope to help make 
The Innovator accessible and easily understood 
by the everyday reader – someone who might 
not necessarily be a medical professional or 
researcher. The medical world fascinates me and 
I am eager to learn more about it every day.
I look forward to keeping you all in the loop 
about the great research happening throughout 
the Baystate Health system. If you have any story 
ideas for The Innovator, please feel free to send 
me an email at allison.litera@baystatehealth.org. 
We would be happy to consider your ideas!
Until next time,
Allie 
Jennifer Pacheco, MPH, CIM, CIP 
was promoted to Director, Healthcare 
Research Compliance and Chief 
Research Compliance Officer for Bay-
state Health, effective October 2018. 
Pacheco joined Baystate‘s Human 
Research Protection Program (HRPP) 
in 2006. Promoted to HRPP Director in 
2013, she has guided the institution and 
its research teams in meeting ethical 
principles and regulatory requirements 
for research. Under her leadership, our 
HRPP implemented process improve-
ments for our IRBs that have greatly 
reduced administrative burden and 
time-to-approval, and passed brilliantly 
two rounds of accreditation from the 
Association for the Accreditation of 
Human Research Protection Programs 
(AAHRPP). 
Pacheco’s new role as Director of 
Healthcare Research Compliance 
and Chief Research Compliance 
Officer gives her a platform to educate 
people about research in public, in the 
hospital, and for medical profession-
als. It also gives a clear, centralized 
institutional voice to research compli-
ance issues. In her new role leading 
the research compliance program, Ms. 
Pacheco will have matrixed report-
ing to the Chief Research Officer and 
to the Chief Compliance & Privacy 
Officer. She will continue to oversee 
administration of the HRPP, and col-
laborate with relevant departments in 
ensuring adherence to research billing 
compliance and research conflict of 
interest policies. Her goals are to make 
the research regulatory personnel 
approachable and available to field any 
questions or concerns; minimize risks 
to research subjects, employees, and 
the institution; advance new standards 
of research practice; and improve 
efficiency in review and monitoring 
to lower the burdens associated with 
healthcare research.
“When people think of research 
compliance, they may get a little 
intimidated,” she explains, “but we are 
here to help. We want get you where 
you need to be, and still get you where 
you’re looking to go.”
If you have any questions about 
research compliance or human 
research protection at Baystate Health, 
call (413) 794-3458 or email jennifer.
pacheco@baystatehealth.org.
Jennifer Pacheco, MPH, CIM, CIP
(Continued from page 1)
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Research at Baystate Franklin Medical Center
As an academic health system, Baystate Health performs research at all of its hospitals as part of its focus on advancing 
care. For example, research has been growing at Baystate Franklin Medical Center in Greenfield, MA. Here we highlight a 
couple of the latest projects occurring there.
SPEECH PATHOLOGY 
RESEARCH WITH AMANDA 
BERNHARD, MA, CCC-SLP
Parkinson’s disease can 
cause problems with speech 
in up to 90% of patients who 
have it. Amanda Bernhard, MA, 
CCC-SLP, is leading research 
at BFMC comparing the effects 
of rehabilitation exercises vs. 
a worn device to combat the 
communication challenges 
presented by Parkinson’s. The 
program that Bernhard offers 
at BFMC is called LSVT LOUD 
(LSVT stands for “Lee Silverman 
Voice Treatment”). Research 
supporting the effectiveness of 
this program dates back to the 
late 1980s. The intensive treat-
ment is used globally to help 
patients with Parkinson’s dis-
ease regain normalcy to their 
speech. The research project 
is hosted at the University of 
Massachusetts Amherst and is 
headed up by Dr. Kelly Richard-
son. The funding is provided by 
the National Institutes of Health 
(NIH).
“LSVT LOUD teaches, 
through various phonation 
and speech exercises, how to 
use a louder voice,” explains 
Bernhard. “It improves respira-
tory strength, vocal volume 
and quality, speech clarity, and 
swallowing function.” Most of 
Bernhard’s patients have many 
“success moments” that they 
share with her. One woman 
told Bernhard that completing 
the LSVT program “restored 
her confidence” and that she 
felt she was able to make her 
voice heard again. Another felt 
so empowered by the LSVT 
program that she felt inspired 
to create a singing group for 
individuals with Parkinson’s 
at a local exercise center. A 
gentleman Bernhard is working 
with at the moment said that 
his daughter, upon hearing his 
louder voice over the phone, 
told him “you sound like you 
did two or three years ago, your 
old voice is back!”
The other treatment option 
used in the research study is 
a device called a SpeechVive; 
a hearing aid-type apparatus 
fitted to and worn by an indi-
vidual, just like a hearing aid. 
When the individual speaks, 
the SpeechVive turns on and 
projects a babbling noise into 
the background. This sound 
encourages the wearer to 
speak louder. The SpeechVive 
was developed and invented 
within the past couple years by 
Jessica Huber, PhD, of Purdue 
University. According to purdue.
edu, “The SpeechVive capital-
izes on the Lombard effect. 
This is the reflex that causes 
us to speak louder, clearer, 
and slower in the presence of 
background noise. All adults 
demonstrate this response. 
People with Parkinson’s dis-
ease have difficulty with speech 
loudness, clarity, and rate. The 
SpeechVive has the potential to 
improve all three domains via 
the Lombard effect.” 
“It is a newer device with not 
a lot of research yet to back up 
its effectiveness, but that’s what 
we’re hoping this study helps 
discover,” informs Bernhard. “It 
seems like it could be an excel-
lent tool for the right patient.” 
The study will follow 12 
participants in each treatment 
group, and documentation of 
the level of each participant’s 
vocal volume and respiratory 
support will be measured to 
see how effective each method 
is and to compare the results of 
the two groups.
“If I can help by contributing 
to the research that assists this 
population, I will be delighted. It 
is such a joy working with these 
individuals,” adds Bernhard. 
“With Parkinson’s patients in 
particular, so many of them 
have amazing things to say and 
unfortunately feel unheard most 
of the time. Giving them a safe, 
fun space to work on their con-
versation abilities is a great part 
of my job. I love that the LSVT 
program is so empowering.” 
Ultimately, Bernhard is 
excited to help her patients 
express their true voices again.
For more information, contact 
Amanda Bernhard, MA, CCC-
SLP at Amanda.Bernhard@
baystatehealth.org or (413) 
773-2411.
RURAL NEW ENGLAND 
HEALTH STUDY WITH PETER 
FRIEDMANN, MD, MPH, 
DFASAM, FACP, PRINCIPAL 
INVESTIGATOR
 Researchers at UMMS-Bay-
state are conducting a study 
funded by the National Institute 
on Drug Abuse (NIDA), Cen-
ters for Disease Control and 
Prevention (CDC), Substance 
Abuse Mental Health Services 
Administration (SAMHSA) and 
the Appalachian Regional Com-
mission to better understand 
the opioid epidemic and the 
availability of health services 
in rural communities in New 
England. 
“In New England’s rural 
areas,” says Dr. Peter Fried-
mann, Principal Investigator, 
“the epidemic of opioid use 
disorder (OUD) and its related 
sequelae of overdose, HIV, 
hepatitis C virus (HCV), sexually 
transmitted infections (STIs) and 
other infectious comorbidities 
present the most substantial 
challenges to public health and 
health care in decades.”
Baystate is one of only 
eight institutions throughout 
the U.S. that received fund-
ing to participate in what has 
become the National Rural 
Opioid Initiative. The research 
team is based at BFMC but is 
working in locations throughout 
the Interstate 91 corridor from 
Greenfield all the way up north 
to the Canadian border.  
“We are looking for people 
who use painkillers or non-
medically inject any type of 
drugs,” says Randall Hoskinson, 
Project Director for the study. 
Study participants complete 
a survey that asks a broad 
range of questions about the 
individual’s experiences with 
substance use, their ability 
or – as is often the case – their 
inability to access different 
services, stigma, and their 
social network. They are also 
tested for HIV, Hepatitis C, and 
syphilis using rapid tests. Blood 
samples are collected from 
those who test positive for viral 
genetics analysis conducted 
through Massachusetts General 
Hospital and the CDC. The 
UMMS-Baystate Research team 
and partners at Dartmouth and 
Tufts will use survey responses 
and blood test results to map 
opioid use and the spread of 
infectious disease throughout 
the region. 
“This information will be 
compared with what is avail-
able in terms of substance 
use treatment, harm reduc-
tion (e.g. needle exchanges 
and naloxone distribution), 
health services, and infectious 
disease specialty care,” adds 
Hoskinson. The data collected 
will help create a better, more 
accessible system of care and 
resources for persons with sub-
stance use disorders in order 
to reduce overdose deaths 
and the spread of infectious 
diseases.
But first, the team must col-
lect the data. To begin recruit-
ing participants, study staff 
goes out into the community 
and talk to people walking 
down the street, or stopping 
into a gas station or conve-
nience store. 
“We start up a general 
conversation,” explains Julie 
Kingsbury, Clinical Research 
Coordinator. “We target people 
who we think might be eligible 
for this study, or to see if they 
may know someone who 
Amanda Bernhard, MA, CCC-SLP, 
a speech-language pathologist at 
Baystate Franklin Medical Center.
(Continued on page 4)
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Lanspa MJ, Gong MN, Schoen-
feld DA, Lee KT, Grissom 
CK, Hou PC, Serpa-Neto A, 
Brown SM, Iwashyna TJ, Yealy 
DM, Hough CL, Brower RG, 
Calfee CS, Hyzy RC, Matthay 
MA, Miller RR 3rd, Steingrub 
JS, Thompson BT, Miller CD, 
Clemmer TP, Hendey GW, 
Huang DT, Mathews KS, Qadir 
N, Tidswell M. Prospective 
Assessment of the Feasibility 
of a Trial of Low Tidal Volume 
Ventilation for Patients with 
Acute Respiratory Failure. Ann 
Am Thorac Soc. 2018 Nov 8.
Wu H, Huffman AM, Whitcomb 
BW, Josyula S, Labrie S, Tou-
gias E, Rahil T, Sites CK, Pilsner 
JR. Sperm mitochondrial DNA 
measures and semen param-
eters among men undergoing 
fertility treatment. Reprod 
Biomed Online. 2018 Nov 16.
Johnson KG, Johnson DC, 
Thomas RJ, Feldmann E, 
Lindenauer PK, Visintainer 
P, Kryger MH. Flow limitation/
obstruction with recovery 
breath (FLOW) event for 
improved scoring of mild 
obstructive sleep apnea with-
out electroencephalography. 
Sleep Med. 2018 Nov 30.
Leung B, Madhuripan N, Bittner 
K, Rastegar V, Banever G, 
Tashjian D, Moriarty K, Polan-
sky S, Tirabassi M. Clinical 
outcomes following identifica-
tion of tip appendicitis on 
ultrasonography and CT scan. 
J Pediatr Surg. 2018 Oct 5.
Al-Azizi KM, Grewal V, Gobeil 
K, Maqsood K, Haider A, 
Mohani A, Giugliano G, Lotfi 
AS. The left distal trans-radial 
artery access for coronary 
angiography and intervention: 
A US experience. Cardiovasc 
Revasc Med. 2018 Oct 25.
Krajewski D, Kaczenski E, 
Rovatti J, Polukort S, Thomp-
son C, Dollard C, Ser-Dolansky 
J, Schneider SS, Kinney SRM, 
Mathias CB. Epigenetic Regula-
tion via Altered Histone Acety-
lation Results in Suppression 
of Mast Cell Function and Mast 
Cell-Mediated Food Allergic 
Responses. Front Immunol. 
2018 Oct 23;9:2414.
Anastasio HB, Campbell LE, 
Buermeyer A, Saccone G, 
Moreno S, Cruz Y, Berghella V, 
Schoen C, Roman A. Nonste-
roidal Antiinflammatory Drug 
Administration and Postpartum 
Blood Pressure in Women 
With Hypertensive Disorders 
of Pregnancy. Obstet Gynecol. 
2018 Nov 5.
Spitzer KA, Stefan MS, Priya 
A, Pack QR, Pekow PS, Lagu 
T, Pinto-Plata VM, ZuWallack 
RL, Lindenauer PK. Participa-
tion in Pulmonary Rehabilita-
tion Following Hospitalization 
for COPD among Medicare 
Beneficiaries. Ann Am Thorac 
Soc. 2018 Nov 12.
Notable Recent Published Papers
Contact Baystate’s Health Science Library for more information at libraryinfo.bhs.org/home
is.” Respondent Driven 
Sampling (RDS) is utilized 
for recruitment. RDS is a 
referral-based system that 
is used to find members 
of hard-to-reach or hidden 
populations. Participants 
are given coupons to 
distribute to other people 
they know who use drugs 
and are given an incentive 
for successful referrals of 
peers that take part in the 
study.
“With this research, we 
are learning from people 
who know firsthand what 
it’s like to use opioids and 
inject drugs and live in a 
rural area, something that 
has been looked at very 
little in the past,” adds Elyse 
Bianchet, Research Assis-
tant. Breaking the stigma 
surrounding addiction is a 
goal as well. 
“People can be afraid to 
admit that they use. They 
may be afraid that we have 
something to do with the 
law. We stress that this is 
100% confidential,” assures 
Kingsbury. Along with con-
fidentiality, what the team 
values most is treating 
participants with respect, 
dignity, and compassion 
without judgement. 
“We reassure them that 
their drug use doesn’t 
define them, and we 
always make it clear we 
appreciate their time and 
input and that their time 
and input is extremely 
valuable,” adds Bianchet. 
“Many people who use 
drugs do so because they 
have experienced a lot 
of trauma. Living in active 
addiction is an ordeal in 
itself. Someone injecting 
heroin every day is not hav-
ing fun. It’s a lonely, painful, 
difficult place.” Thus, the 
majority of participants are 
enthusiastic that the study 
is taking place because 
they want to help make the 
situation better for others 
across New England. 
“They know this is 
important work, and they 
are eager and proud to 
be a part of it,” adds Eric 
Romo, a MD-PhD student 
at UMMS-Worcester who 
is working with the team. 
Even with the success 
they have had recruiting, 
almost 400 participants 
since Memorial Day, there’s 
still a bit of mystery to the 
community of drug users as 
a whole. 
“All in all, we will never 
be sure of how many peo-
ple use opioids,” concludes 
Kingsbury. “There’s a whole 
population that doesn’t 
want to be known.”
For more information 
on the Rural New England 
Health Study, or to find out 
how to participate, contact 
Julie Kingsbury at Julie.
Kingsbury@baystatehealth.
org or (413) 773-4422.
Julie Kingsbury, Clinical 
Research Coordinator; Ely 
Bianchet, Research Assistant; 
and Eric Romo, MD-PhD student 
at UMMS-Worcester, outside of 
BFMC’s Research Offices.
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